Early skin cancer is curable.
Early access is attainable.
SkinAware can help.
SkinAware delivers AI-powered skin cancer detection and triage through any standard smartphone — no hardware, no waiting lists, no compromise on accuracy.
Request a Pilot
The Problem
John found a spot on his arm.
The wait almost killed him.
John is 55. He's a farmer in rural Nebraska. One morning he notices something new on his forearm.
He looks for a dermatologist. The closest one is four hours away and has a nine-month waiting list. He tries his primary care physician. She hasn't seen many lesions like this. She isn't sure. She makes an uncomfortable referral and hopes for the best.
This is not an edge case. This is the everyday reality for tens of millions of Americans — and the consequences can be fatal. The healthcare system is failing them, and existing technology hasn't fixed it.

John's story is representative of a systemic failure — not a rare exception. Every month of delay increases mortality risk and treatment cost exponentially.
The Scale of the Crisis
Dermatology access is broken
60% of U.S. counties have zero dermatologists. That's not a rural inconvenience — it's a structural failure that creates a deadly bottleneck between patients and life-saving care. The costs for the patients and the healthcare system are unacceptable.
The map tells the story clearly. Red means high need, limited access — and red dominates the American heartland. Patients are forced to wait 9+ months and drive hours. Frontline providers are forced to make high-stakes decisions without the tools or training to make them safely.
99%
Early-Stage Survival
Nearly all early-stage skin cancers are curable with prompt detection and treatment.
30%
Late-Stage Survival
Only 1 in 3 patients survive late-stage melanoma. Delay is the difference.
+20%
Mortality Gap
Patients in underserved communities face 20% higher melanoma mortality than those with access.
$150K
Extra Cost Per Late Diagnosis
Late-stage treatment costs over $150,000 more per patient than early intervention.
Sources: HRSA AHRF 2024; Merritt Hawkins Physician Access Survey; NCI SEER; Guy GP et al., J Am Acad Dermatol
Why Existing Tools Fail
The current solutions aren't enough
From consumer apps to specialized devices to telemedicine workarounds, the market is full of partial answers. What's missing is a solution that is simultaneously clinically validated, universally accessible, and seamlessly integrated into real care pathways.
🤖 General AI Tools
No validated clinical accuracy. General-purpose internet-based AI models were not built for diagnostic triage. They carry no clinical validation and cannot be trusted for provider-grade decisions. Using them in a clinical setting creates liability, not clarity.
📱 Consumer Apps
Low trust, low clinical utility. Consumer-facing skin apps are optimized for engagement, not accuracy. They lack the sensitivity needed to safely rule out malignancy and are not designed to integrate into provider workflows or influence clinical decisions.
🔬 Hardware Devices
Costly, inaccessible infrastructure. Hardware-dependent solutions require expensive proprietary devices, making them unaffordable and impractical for rural clinics, community health centers, and mobile outreach programs — exactly where the need is greatest.
📞 Teledermoscopy
Scheduling burden, access barriers. Asynchronous teledermatology shifts the bottleneck rather than removing it. It still requires specialist time, adds scheduling complexity, and relies on infrastructure that underserved clinics often don't have.
Sources: Freeman K et al., BMJ 2020; FDA Clinical Decision Support Guidance; Finnane A et al., JAMA Dermatol
Clinical Demand
Clinicians Are Already Using AI
~65%
of physicians are already using AI
Most say it makes them better at their jobs.
The question is no longer whether clinicians trust AI. It's where it actually delivers value.
The Solution
Skin cancer detection on every phone, everywhere.
No hardware. No waiting list. No compromise.
SkinAware turns any standard smartphone into a clinical-grade skin cancer triage tool. A patient or provider takes a photo of a suspicious lesion. Our AI — validated on over 217,000 clinical images across all Fitzpatrick skin tones — analyzes it in seconds.
For patients like John, it means knowing within minutes whether a lesion needs urgent attention — and getting connected to the right care immediately. For providers like his PCP, it means confident triage without specialist training. For health systems and payers, it means fewer late-stage diagnoses and dramatically lower costs.
How It Works
Clinical-Grade AI
Built for the clinic. Ready for the real world.
Proprietary deep learning ensemble imaging system and model ensure accurate and reproducible analysis.
92% Sensitivity
Correctly identifies malignant lesions. No dangerous lesion goes missed. This is the standard that matters most — a missed cancer is a catastrophic outcome.
80% Specificity
Correctly identifies benign lesions, minimizing unnecessary referrals that burden specialists and create anxiety for patients who don't need escalation.
217,000+ Images
Validated on the ISIC/Slice-3D dataset — the gold standard in dermatology AI — across all six Fitzpatrick skin tones, ensuring equity in performance.
Zero Hardware
Runs on any standard smartphone. No proprietary device. No clinic infrastructure upgrade required. Ready to deploy wherever a provider has a phone.
Internal validation across multiple published datasets. Contact us for details.
Who It's For
Value across the entire care ecosystem.
The access crisis in dermatology touches every stakeholder — patients, providers, and payers all bear the cost of late detection. SkinAware creates meaningful, measurable value for each of them.
Patients
No more months of waiting and growing anxiety. SkinAware puts clinical-grade assessment in the hands of anyone with a smartphone — enabling earlier detection, faster referrals, and treatment that starts up to 8 months sooner. For patients in underserved communities, this is the difference between a routine procedure and a life-altering diagnosis.
Providers
Primary care physicians, wound care nurses, and mobile clinic staff finally have a tool that matches their reality. SkinAware delivers confident triage without specialist training — empowering frontline clinicians to act decisively rather than refer unnecessarily or delay uncomfortably. Capture more procedures. Reduce liability. Strengthen patient trust.
Health Systems & Payers
Every late-stage melanoma diagnosis costs over $150,000 more than an early one. SkinAware drives systemwide savings by reducing unnecessary specialist referrals, improving triage efficiency, and enabling earlier intervention across populations. Better outcomes. Higher satisfaction. Measurable ROI from day one of deployment.
Founder Story

Access to care is our personal obligation.
Kevin Phelan, MD, FACS is a surgeon and combat veteran. He has delivered care in some of the most resource-constrained environments on earth — forward operating bases, field hospitals, communities with nothing. He knows what it looks like when the system fails people who have no fallback.
When his own father spent months waiting to see a dermatologist for a suspicious lesion, Kevin saw the same systemic failure play out in the most personal way possible. A trained surgeon, watching his father wait. Knowing the math. Knowing what delay costs.
That's why he built SkinAware - because the status quo is clinically indefensible and morally unacceptable. He assembled a team with the same conviction: that technology exists to close this gap right now, and waiting is no longer an option.
"Is this safe care for the patient? Is this acceptable risk for the clinician? The answer to both must be no — and that's exactly why we built SkinAware."
— Kevin Phelan, MD, CEO
Kevin Phelan, MD, FACS — CEO
Surgeon and combat veteran with deep experience delivering care in resource-constrained environments. Firsthand understanding of both the clinical problem and the human cost of delay.
Kyisin Aung, MPH — COO
Public health leader with expertise in health equity, program implementation, and scaling impact in underserved communities across complex healthcare systems.
Nick Lind, MBA — Lead Engineer
Technical and AI expert specializing in healthcare machine learning, model architecture, and scalable software infrastructure for clinical applications.
Why Now
The moment for this solution is here.
Three powerful forces have converged to make SkinAware not just possible, but inevitable. The question is no longer whether AI-powered skin triage will transform dermatology access — it's who will lead that transformation.
Telehealth Infrastructure
Post-pandemic telehealth expansion has normalized remote clinical encounters and digital triage. Health systems are actively seeking tools that extend this infrastructure into new clinical domains.
AI Adoption in Healthcare
Clinical AI is moving from experimental to standard of care. FDA guidance on clinical decision support has created a clear regulatory pathway for solutions like SkinAware to enter care workflows with confidence.
Workforce Shortages
The U.S. faces a critical and worsening shortage of dermatologists, especially outside major metro areas. No amount of training pipeline expansion will close this gap. Intelligent triage tools are the only scalable answer.

SkinAware is positioned at the intersection of all three trends — clinically validated, infrastructure-agnostic, and designed for the care settings where the workforce shortage bites hardest.
Traction & Pilots
Early partners are already at the table.
SkinAware is entering the market with a focused pilot strategy targeting the care settings where the access gap is most acute and the clinical need is most immediate. Early pilots are launching with a range of key clinical partners and organizational stakeholders — groups that have felt the pain of this problem firsthand and are actively looking for a validated solution.
Interest from health system leaders and impact-focused investors reflects a broader recognition that the timing is right and the technology is ready. We are not asking partners to take a risk on unproven AI. We are inviting them to be early leaders in a clinical transformation that is already underway.
If you lead a health system, operate within key care settings, or invest in solutions that save lives at scale — the conversation starts now.
Strategic Care Partners
Frontline providers gaining confident triage tools for their most uncertain clinical encounters.
Regional Pilot Programs
Care in various settings — just a device, a patient, and a clinical recommendation in seconds.
Institutional Stakeholders
Routine skin assessment capabilities for populations who rarely access specialists.
Digital Integration Partners
Asynchronous triage without complex scheduling — integrated into existing digital workflows.
SkinAware Foundation
Advancing Global Health Equity: Bringing SkinAware to Every Community
The SkinAware Foundation serves as the dedicated clinical implementation arm, extending the reach of our innovative technology to the world's most underserved and under-resourced populations. Our mission is to dismantle barriers to skin cancer detection, deploying SkinAware where the need is greatest – in communities lacking any dermatology access.
We bridge the gap between cutting-edge innovation and real-world impact in low-resource settings, proving that this technology can empower health workers anywhere, for anyone. Through strategic partnerships with global health organizations, NGOs, and local community health workers, the Foundation is making equitable access to critical dermatological care a reality.
Global Deployment
Reaching populations with critical needs, regardless of geographic location or infrastructure.
Health Equity
Focusing on equitable access to specialist-level care where it is currently non-existent.
Community Partnerships
Collaborating with local organizations to integrate SkinAware into existing health programs.
Veteran Support
Ensuring veterans in remote areas receive timely skin cancer screenings and care.
Help us bring early detection to everyone, everywhere.
Skin cancer is one of the most common and most preventable cancers in the world. Detected early, the survival rate approaches 99%. The only barrier is access — and SkinAware removes it. Join us in making early detection a right, not a privilege.
For Health Systems & Partners
Request a pilot deployment. See SkinAware in action within your existing care pathways. We handle onboarding, training, and integration — you deliver better outcomes.
For Investors
SkinAware sits at the intersection of AI, health equity, and scalable impact. We're raising to accelerate pilots, pursue FDA clearance, and expand to underserved markets globally.
For Everyone Else
Follow our journey. Share our mission. Help us reach the patients, providers, and partners who need this most. Early detection saves lives — spread the word.